Business Wire

ACAMS 14th Annual AML & Financial Crime Conference - Europe

Share

Regulatory changes and technological disruption are currently reshaping European Anti-Financial Crime initiatives. ACAMS’ 14th Annual European AML & Financial Crime Conference brings together industry leading experts to offer insight on the new skills, tools and strategies that will help compliance professionals successfully navigate this era of rapid change. The conference, centered on the theme “Mastering the New Era of European Compliance” will take place at the RAI Amsterdam, Netherlands from May 31 – June 1, 2018. The conference includes a keynote presentation by Alexandra Jour-Schroeder, director for criminal justice at the European Commission, on 5AMLD and its practical implications for compliance professionals.

“The role of the AML professional is quickly evolving from one of sub-area specialists to those with a broader knowledge base and diverse skills,” said Rick McDonell, executive director of ACAMS and former executive secretary for the Financial Action Task Force. “Accelerating the evolution of AML compliance practices and professionals will require greater dialogue between the private sector, enforcement bodies and regulators – something ACAMS is well-positioned to facilitate.”

The Europe conference provides in-depth training, regulatory updates and critical solutions to regional AML compliance challenges. It is the largest dedicated AML conference in the region, and represents a unique opportunity for the AML/CTF/anti-financial crime community to meet. Plenary sessions will address topics as 4AMLD & GDPR, Sanctions, the Terrorism Threat in Europe and Cybercrime. Specialist ‘AML Knowledge’ and ‘AML Innovations’ tracks will spotlight the latest breakthroughs in sector technology.

“The pace of change in European anti-financial crime policy and practice continues unabated, and topics like artificial intelligence, cybercrime, AML data analytics and how to combat terror financing and human trafficking have never been more important,” said Angela Salter, head of Europe at ACAMS. “This conference brings together current and future leaders of our industry to learn from one another and to connect with their peers across both private and public sectors. We’re proud to be the catalyst for this sharing of cutting-edge best practice and anti-financial crime professional development.”

Led by industry leaders in banking, government and law enforcement, the Europe Conference’s panels and workshops tackle critical AML issues head-on, with thought-provoking sessions, such as:

  • Cybercrime: Can it Ever be Prevented?
    • Analyze recent cybercrime cases to highlight the current cyber threat landscape
    • Create models for common cyber-typologies and red flags indicating potential cybercrime activities
    • Create a cyber-event response plan to investigate damage, restore systemic integrity and notify stakeholders including law enforcement and regulators
  • Compliance with Converging Regulation: A Holistic Approach Towards the Implementation of 4AMLD/ GDPR & PSD2
    • Raise awareness of regulatory impact assessments as a tool for more effective regulatory change planning
  • Making the Invisible More Visible: Tackling Bribery and Corruption
    • Examine recent FCPA prosecutions of European entities and lessons learned from them
    • Review approaches taken by other financial institutions to identify the behavior of customer involved in bribery and corruption
  • The Ever-Changing Specter of Sanctions Risks
    • Evaluate the impact of the current evolving global political landscape in Venezuela, Russia, Cuba, Myanmar and others, and sanction screening activities
    • Learn about new and emerging evasion techniques used sanctions targets to gain access to the global financial system

Speakers include:

  • Remy Jansen, Head of Department De Nederlandsche Bank, Netherlands
  • Erik Barnett, Europe Regional Head of Financial Crime Threat Mitigation, HSBC
  • Sharon Campbell, Global Head of Financial Crime Compliance, Nordea
  • Geraldine Lawlor, Global Head of Financial Crime, Barclays
  • Philippe Vollot, Managing Director, Global Head of AFC & Group Anti-Money Laundering Officer, Deutsche Bank
  • Eric Strom, Cyber Specialist, FBI, Netherlands
  • Andy McDonald, former Head of UK National Terrorist Financial Investigation Unit, New Scotland Yard, United Kingdom

For more information and to download a full conference schedule, visit http://www.acamsconferences.org/europe.

Editor’s Note: Members of the media may contact Ernie Gibble (ernie.gibble@adtalem.com) at +1 630.353.9920 for credentials to cover the conference.

About the Association of Certified Anti-Money Laundering Specialists ® (ACAMS ® )

ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a global education provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime professionals from a wide range of industries, with extensive resources designed to develop and sharpen the skills required for superior job performance and career advancement. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Visit acams.org for more information.

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading global education provider, and the parent organization of Adtalem Educacional do Brasil, American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Carrington College, Chamberlain University, DeVry University and its Keller Graduate School of Management, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com.

Contact information

Media Contact for Conference Attendance:
Adtalem Global Education
Ernie Gibble
o: +1.630.353.9920
m: +1.773.454.7132
ernie.gibble@adtalem.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu